Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients
✍ Scribed by Janusz K. Rybakowski; Maria Skibinska; Aleksandra Suwalska; Anna Leszczynska-Rodziewicz; Leszek Kaczmarek; Joanna Hauser
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 67 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.1182
No coin nor oath required. For personal study only.
✦ Synopsis
Objective:
Matrix metalloproteinase 9 (mmp-9) has been implicated in a number of pathological conditions including cancer and heart diseases, and recently also in such neuropsychiatric disorders as schizophrenia and bipolar illness. therefore, we investigated a possible association between functional polymorphisms of the mmp-9 gene and the response to lithium, the main mood-stabilizing drug in bipolar illness.
Methods:
One hundred and nine bipolar patients treated with lithium for at least 5 years were analyzed. the lithium response was assessed as--excellent: no affective episodes during lithium treatment; partial: 50% or more reduction in the episode index; no response: less than 50% reduction, no change or worsening in the episode index. the -1562c/t mmp-9 gene polymorphism (rs3918242) was assessed by pcr-rflp method.
Results:
Genotype distributions were not in hardy-weinberg equilibrium. no association was found between polymorphism studied and the quality of response to prophylactic lithium administration.
Conclusion:
The functional polymorphism of the mmp-9 gene, analyzed in this study, may not be associated with the treatment response to lithium in bipolar patients.